# non-active secondary progressive multiple sclerosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/non-active-secondary-progressive-multiple-sclerosis

> No upcoming FDA catalysts in non-active secondary progressive multiple sclerosis; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 23, 2025 | [Foralumab trial start](https://sec-api.dev/pdufa/foralumab) | TLSA | non-active secondary progressive multiple sclerosis | completed | "TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390025034332/ea023921901ex99-1_tiziana.htm)) |
| Mar 2026 | [Orelabrutinib trial start](https://sec-api.dev/pdufa/orelabrutinib) | ZBIO | non-active secondary progressive multiple sclerosis | completed | "In March of 2026, we initiated a second global, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib dosed 80 mg QD compared to placebo in patients with non-active secondary progressive multiple sclerosis, with a primary endpoint of time to onset of 24-week CDP." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123876/tm2629107-1_424b5.htm)) |
| April 2026 | [Foralumab tzls-401 100 µg primary completion](https://sec-api.dev/pdufa/foralumab-tzls-401) | TLSA | Non-Active Secondary Progressive Multiple Sclerosis | delayed | "NCT06890923 (Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-04-30 (ESTIMATED); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890923)) |

## Drugs

- [Foralumab](https://sec-api.dev/pdufa/foralumab) (TLSA)
- [Orelabrutinib](https://sec-api.dev/pdufa/orelabrutinib) (ZBIO)
- [Foralumab tzls-401 100 µg](https://sec-api.dev/pdufa/foralumab-tzls-401) (TLSA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/non-active-secondary-progressive-multiple-sclerosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "non-active secondary progressive multiple sclerosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/non-active-secondary-progressive-multiple-sclerosis

```bibtex
@misc{secapidev_indications_non_active_secondary_progressive_multiple_sclerosis_20261116,
  title        = {non-active secondary progressive multiple sclerosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/non-active-secondary-progressive-multiple-sclerosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_non_active_secondary_progressive_multiple_sclerosis_20261116","title":"non-active secondary progressive multiple sclerosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/non-active-secondary-progressive-multiple-sclerosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
